Arnold Washton

Learn More
In an open clinical trial, lofexidine, an alpha-noradrenergic agonist similar to clonidine, was administered to 30 opiate-dependent outpatient volunteers following abrupt discontinuation of chronic methadone or levo-alpha acetylmethadol (LAAM). Lofexidine significantly reduced opiate withdrawal symptoms without the adverse sedative and hypotensive effects(More)
A discussion is provided of clinical techniques for establishing abstinence and preventing relapse in cocaine addicts within the context of an intensive outpatient treatment program. A basic tenet of this article is that to produce higher success rates in these and other drug-dependent patients more attention must be paid to some very fundamental treatment(More)
This study investigated gender differences in the relationship between psychoactive substance use and sexual thoughts, feelings, and behaviors. Participants (N = 464) were male and female alcohol, opiate, cocaine, and methamphetamine users enrolled in an outpatient treatment program at any of 8 sites. A self-report survey that inquired about the specific(More)
Treatment outcomes were compared for 2 groups of subjects detoxified from methadone using clonidine. One group of 12 subjects was encouraged to continue in treatment with naltrexone, while the other 12 subjects did not have naltrexone treatment available. Results suggested that those subjects who had naltrexone available were more successful at completing(More)
We examined naloxone-precipitated withdrawal as a means for rapid opiate detoxification and induction onto naltrexone. In 29 patients dependent on methadone (5 to 20 mg/day), abstinence was precipitated by an injection of naloxone. Repeated injections of naloxone were given subsequently until symptoms of abstinence were no longer induced. Successive(More)
The aim of this paper is to review and explore the psychopharmacology of cocaine from two divergent points of view--the chronic user and the laboratory. Cocaine's behavioral effects will be correlated with neurophysiological, neurochemical events, and reports by users of consequences of chronic use. These studies and reports when pieced together offer(More)
Naltrexone, an orally administered, synthetic, long-acting narcotic antagonist, is being reviewed by the Food and Drug Administration (FDA). Specifically, the FDA is reviewing the preclinical (toxicology, reproduction and teratology, and carcinogenicity studies) and clinical (Phase I, Phase II, and Phase III) data to determine if the drug is safe and(More)